Core Viewpoint - Baicheng Pharmaceutical has entered into a collaboration agreement with Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. for the BIOS-0629 project, focusing on research, clinical trials, and commercialization in the Greater China region [1] Group 1: Collaboration Details - The agreement stipulates that Baicheng Pharmaceutical will handle research and development, clinical trials, and registration for the product [1] - Zhejiang Zhongshen will be responsible for R&D transformation, production, sales, and market expansion in the Greater China region [1] Group 2: Financial Terms - Following the signing of the contract, Zhongshen will pay milestone payments totaling 300 million yuan based on R&D progress [1] - Baicheng Pharmaceutical will receive a 10% commission on sales revenue after the product is launched in the Greater China market [1]
百诚医药就BIOS-0629项目签署《技术开发合作协议》